Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Receivables: 2018-2024

Historic Change in Receivables for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $904,000.

  • Silence Therapeutics' Change in Receivables rose 96.46% to -$62,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 119.77%. This contributed to the annual value of $904,000 for FY2024, which is 330.61% up from last year.
  • Silence Therapeutics' Change in Receivables amounted to $904,000 in FY2024, which was up 330.61% from -$392,000 recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Change in Receivables ranged from a high of $37.8 million in FY2021 and a low of -$37.6 million during FY2020.
  • For the 3-year period, Silence Therapeutics' Change in Receivables averaged around $411,667, with its median value being $723,000 (2022).
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 736,642.77% in 2020, then skyrocketed by 330.61% in 2024.
  • Silence Therapeutics' Change in Receivables (MRY) stood at -$37.6 million in 2020, then skyrocketed by 200.49% to $37.8 million in 2021, then tumbled by 98.09% to $723,000 in 2022, then tumbled by 154.22% to -$392,000 in 2023, then soared by 330.61% to $904,000 in 2024.
  • Its last three reported values are $904,000 in FY2024, -$392,000 for FY2023, and $723,000 during FY2022.